What does this research mean for the field?

Ibrutinib can act as a unifying causative agent for severe, multisystem complications—including atrial fibrillation, bleeding, and infections—in elderly patients, which can be critically exacerbated by complex drug interactions. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To document a case of severe, multisystem toxicities linked to ibrutinib therapy in an elderly patient with a low-grade B-cell lymphoproliferative disorder.

September 3, 2026CureusOpen Access

Ibrutinib as the Unifying Culprit: A Case Report of Multisystem Complications in an Elderly Patient With Low-Grade B-Cell Lymphoproliferative Disorder

View Full Paper

Ask AI

Bookmark

To document a case of severe, multisystem toxicities linked to ibrutinib therapy in an elderly patient with a low-grade B-cell lymphoproliferative disorder.
Clinical evaluation of an 82-year-old female with CD5-negative low-grade B-cell lymphoproliferative disorder and IgM paraproteinaemia treated sequentially with rituximab and ibrutinib.
Retrospective analysis of the patient's adverse events, medication regimen, and concurrent drug interactions involving apixaban and clarithromycin.
Ibrutinib administration was associated with a cascade of severe adverse events, including recurrent infections, platelet dysfunction, and new-onset paroxysmal atrial fibrillation.
The patient suffered life-threatening bleeding and cardiovascular emergencies, specifically a post-fall haemothorax and pericardial tamponade requiring urgent pericardiocentesis.
Co-prescription of apixaban for atrial fibrillation and clarithromycin for a lower respiratory tract infection introduced hazardous drug-drug interactions that compounded bleeding risk.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Case report demonstrates severe multisystem complications from ibrutinib in an elderly patient, highlighting dangerous drug interaction risks and the need for close monitoring.

Cite This Study

Ghalib et al. (2026) studied this question.

synapsesocial.com/papers/6a9934cf636c6408cfa7c94b https://doi.org/10.7759/cureus.115495

View Full Paper

Ask AI

Bookmark

Implication

Case report demonstrates severe multisystem complications from ibrutinib in an elderly patient, highlighting dangerous drug interaction risks and the need for close monitoring.

Ibrutinib as the Unifying Culprit: A Case Report of Multisystem Complications in an Elderly Patient With Low-Grade B-Cell Lymphoproliferative Disorder

Key Points

Discussion

Implication

Cite This Study

Ibrutinib as the Unifying Culprit: A Case Report of Multisystem Complications in an Elderly Patient With Low-Grade B-Cell Lymphoproliferative Disorder

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider